Eric M. Dube Sells 21,125 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube sold 21,125 shares of Travere Therapeutics stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $243,360.00. Following the sale, the chief executive officer now owns 361,975 shares of the company’s stock, valued at $4,169,952. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock traded up $1.88 during trading on Monday, reaching $12.86. The company’s stock had a trading volume of 4,209,742 shares, compared to its average volume of 1,242,490. The business’s 50-day moving average price is $9.30 and its 200-day moving average price is $7.86. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $14.62. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96. The firm has a market cap of $979.02 million, a PE ratio of -6.12 and a beta of 0.71.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. The business had revenue of $54.12 million for the quarter, compared to analyst estimates of $49.50 million. Equities analysts forecast that Travere Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TVTX shares. Guggenheim raised Travere Therapeutics from a “neutral” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Monday. Barclays boosted their price target on Travere Therapeutics from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Wedbush lifted their price target on shares of Travere Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Citigroup boosted their target price on Travere Therapeutics from $14.00 to $23.00 and gave the stock a “buy” rating in a report on Friday. Finally, Bank of America increased their price target on Travere Therapeutics from $18.00 to $19.00 and gave the company a “buy” rating in a report on Friday. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $16.92.

Institutional Trading of Travere Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Forefront Analytics LLC lifted its holdings in shares of Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after buying an additional 1,237 shares in the last quarter. ProShare Advisors LLC raised its stake in Travere Therapeutics by 9.2% in the first quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock worth $142,000 after buying an additional 1,557 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in Travere Therapeutics by 3.8% during the second quarter. Rice Hall James & Associates LLC now owns 76,174 shares of the company’s stock valued at $626,000 after buying an additional 2,774 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Travere Therapeutics by 10.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company’s stock worth $240,000 after buying an additional 2,948 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Travere Therapeutics by 8.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 50,178 shares of the company’s stock valued at $387,000 after purchasing an additional 3,754 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.